The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several ...

The hospital lobby wants the Trump administration to investigate Johnson & Johnson, Eli Lilly, Sanofi, Novartis and Bristol ...

The American Hospital Association is calling on federal regulators to launch an antitrust investigation into its claims of drug manufacturers’ actions regarding 340B rebate models. In a letter sent to ...

The American Hospital Association wants the Health Resources and Services Administration to levy monetary penalties against Johnson & Johnson if the drug company continues with its plan to give 340B ...

The pharmaceutical lobby is ramping up its opposition to nonprofit health systems’ expanding use of the 340B Drug Discount ...

The 340B Drug Pricing Program was created to help a targeted group of safety net providers care for low-income and uninsured patients. First enacted as part of the Veterans Healthcare Act of 1992 ...

The 100% woman-owned consulting firm partners with healthcare organizations to help them understand, implement, and optimize ...

The Trump administration will pilot a voluntary program next year in which pharmaceutical companies can offer rebates for certain drugs to hospitals participating in the 340B drug discount program.

“HRSA’s attempts to bar J&J from bringing transparency to the 340B Program through implementation of the rebate model are fundamentally at odds with the 340B statute, the Administrative ...

AHA letter to the Federal Trade Commission and Department of Justice regarding anticompetitive activity by drug companies with respect to 340B “rebate models.” ...